Literature DB >> 33269821

Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway.

Gang Li1, Dongxin Xu2, Jinju Sun3, Shiyun Zhao4, Dan Zheng5.   

Abstract

BACKGROUND: Breast cancer has the highest incidence and mortality among all cancers in women. Paclitaxel (PTX) has a notable therapeutic effect on cancer in clinical practice.
OBJECTIVES: To explore the effect and mechanism of PTX on the proliferation, apoptosis and invasiveness of breast cancer cells.
MATERIAL AND METHODS: MCF-7 cells were treated with PTX (0 μM, 0.01 μM, 0.1 μM, 1 μM) for 48 h. Cell viability was detected using MTT assay and lactate dehydrogenase (LDH) assay; the cell proliferation rate was detected using 5-ethynyl-2'-deoxyuridine (EdU) assay to screen the most effective concentration of PTX. MCF-7 cells were then divided into 5 groups: control group, PTX group, oe-PI3K group, NC-PI3K group, and oe-PI3K+PTX group. Cell apoptosis and cell cycles were detected with flow cytometry; cell invasion was determined using a transwell assay; western blot and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) were used to measure the mRNA and protein expression level of cleaved caspase-3, Bax, Bcl-2, matrix metalloproteinase 9 (MMP-9), vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473).
RESULTS: Paclitaxel inhibited cell viability and proliferation in a dose-dependent manner. In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased. However, PI3K upregulation can reverse the effects of PTX.
CONCLUSIONS: Paclitaxel could inhibit MCF-7 cell proliferation and invasion, and promote MCF-7 cell apoptosis by downregulating the expression of p-AKT (Thr308) and p-AKT (Ser473) in the PI3K/AKT signaling pathway.

Entities:  

Keywords:  PI3K/AKt signaling pathway; apoptosis; breast cancer; paclitaxel; proliferation

Year:  2020        PMID: 33269821     DOI: 10.17219/acem/127681

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  4 in total

1.  Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells.

Authors:  Alejandro Español; Yamila Sanchez; Agustina Salem; Jaqueline Obregon; Maria Elena Sales
Journal:  World J Clin Oncol       Date:  2022-06-24

2.  Ultrasound-targeted microbubble destruction-mediated miR-144-5p overexpression enhances the anti-tumor effect of paclitaxel on thyroid carcinoma by targeting STON2.

Authors:  Xuefeng Chen; Xinyuan Zhang; Yangyang Qian; Enhui Xia; Yu Wang; Qi Zhou
Journal:  Cell Cycle       Date:  2022-02-20       Impact factor: 5.173

3.  Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies.

Authors:  Md Shahin Alam; Adiba Sultana; Md Selim Reza; Md Amanullah; Syed Rashel Kabir; Md Nurul Haque Mollah
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

4.  Synergistic Antiproliferative Effects of All-Trans Retinoic Acid and Paclitaxel on Autosomal Dominant Polycystic Kidney Disease Epithelial Cells.

Authors:  Que Thanh Thanh Nguyen; Thi Xoan Hoang; Hyunjin Ryu; Kook-Hwan Oh; Jae Young Kim
Journal:  Biomed Res Int       Date:  2021-10-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.